{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:34:33Z","timestamp":1793237673630,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,1]],"date-time":"2027-07-01T00:00:00Z","timestamp":1814400000000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["1R43HD112213-01A1"],"award-info":[{"award-number":["1R43HD112213-01A1"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["ZIAHD000640"],"award-info":[{"award-number":["ZIAHD000640"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ymthe.2026.03.020","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:56:36Z","timestamp":1774338996000},"page":"4169-4180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A cartilage-targeted IGF-1-antibody fusion protein as a new therapeutic approach for IGF-1 deficiency"],"prefix":"10.1016","volume":"34","author":[{"given":"Krishma","family":"Tailor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Stowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirtal","family":"Hansdah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Courtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Rama-Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Sisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"van Ree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van Deursen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0611-4901","authenticated-orcid":false,"given":"Julian C.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.03.020_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-nutr-061121-091112","article-title":"Nutrition, Other Environmental Influences, and Genetics in the Determination of Human Stature","volume":"44","author":"Lui","year":"2024","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.ymthe.2026.03.020_bib2","series-title":"Sperling Pediatric Endocrinology","first-page":"299","article-title":"11 - Disorders of Childhood Growth","author":"Jorge","year":"2021"},{"key":"10.1016\/j.ymthe.2026.03.020_bib3","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMcp1213178","article-title":"Clinical practice. Short stature in childhood--challenges and choices","volume":"368","author":"Allen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.03.020_bib4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/apa.1991.80.s377.96","article-title":"Growth hormone receptor deficiency (Laron syndrome): clinical and genetic characteristics","volume":"377","author":"Guevara-Aguirre","year":"1991","journal-title":"Acta Paediatr. Scand. Suppl."},{"key":"10.1016\/j.ymthe.2026.03.020_bib5","series-title":"Handbook of Biologically Active Peptides","first-page":"1627","article-title":"Chapter 222 - Insulin-like Growth Factor-1","author":"Bentov","year":"2013"},{"key":"10.1016\/j.ymthe.2026.03.020_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41434-022-00329-2","article-title":"Toward gene therapy of Laron syndrome","volume":"29","author":"Werner","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.03.020_bib7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(06)69205-2","article-title":"Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature?","volume":"368","author":"Rosenbloom","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.03.020_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1515\/JPEM.2008.21.4.301","article-title":"Insulin-like growth factor-I (rhIGF-I) therapy of short stature","volume":"21","author":"Rosenbloom","year":"2008","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2026.03.020_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2165\/00126839-200506020-00008","article-title":"Mecasermin rinfabate: insulin-like growth factor-I\/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I\/rhIGFBP-3","volume":"6","year":"2005","journal-title":"Drugs R. D"},{"key":"10.1016\/j.ymthe.2026.03.020_bib10","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1210\/jc.2006-1610","article-title":"Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity","volume":"92","author":"Chernausek","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2026.03.020_bib11","first-page":"1504","article-title":"Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study","volume":"86","author":"Backeljauw","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2026.03.020_bib12","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1530\/EJE-07-0187","article-title":"IGF-I therapy in growth disorders","volume":"157","author":"Rosenfeld","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ymthe.2026.03.020_bib13","first-page":"259","article-title":"Experience with insulin-like growth factor I (IGF-I) treatment of growth hormone insensitivity syndrome (GHIS)","volume":"12","author":"Ranke","year":"1999","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2026.03.020_bib14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1515\/JPEM.1995.8.3.149","article-title":"Three year IGF-I treatment of children with Laron syndrome","volume":"8","author":"Klinger","year":"1995","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2026.03.020_bib15","first-page":"273","article-title":"Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency\/Laron syndrome","volume":"77","author":"Vaccarello","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2026.03.020_bib16","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s11095-015-1636-z","article-title":"Human monoclonal antibody fragments targeting matrilin-3 in growth plate cartilage","volume":"32","author":"Cheung","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2026.03.020_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ymthe.2019.01.017","article-title":"Cartilage-Targeted IGF-1 Treatment to Promote Longitudinal Bone Growth","volume":"27","author":"Lui","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.020_bib18","article-title":"Efficacy of cartilage-targeted IGF-1 in a mouse model of growth hormone insensitivity","volume":"15","author":"Tailor","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ymthe.2026.03.020_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"key":"10.1016\/j.ymthe.2026.03.020_bib20","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s42003-021-02565-5","article-title":"In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance","volume":"4","author":"Shan","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymthe.2026.03.020_bib21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ng0196-88","article-title":"Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse","volume":"12","author":"Wajnrajch","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2026.03.020_bib22","doi-asserted-by":"crossref","first-page":"51037","DOI":"10.18632\/oncotarget.17558","article-title":"Structural basis of a novel heterodimeric Fc for bispecific antibody production","volume":"8","author":"Wei","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2026.03.020_bib23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1172\/JCI0215463","article-title":"Circulating levels of IGF-1 directly regulate bone growth and density","volume":"110","author":"Yakar","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.03.020_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1530\/EJE-20-0325","article-title":"Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome","volume":"184","author":"Bang","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ymthe.2026.03.020_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000371798","article-title":"Effectiveness and Safety of rhIGF-1 Therapy in Children: The European Increlex\u00ae Growth Forum Database Experience","volume":"83","author":"Bang","year":"2015","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.ymthe.2026.03.020_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3835(03)00159-9","article-title":"The insulin-like growth factor system and cancer","volume":"195","author":"LeRoith","year":"2003","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2026.03.020_bib27","first-page":"3","article-title":"Insulin-like growth factors and their binding proteins: Biological actions","volume":"16","author":"Jones","year":"1995","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ymthe.2026.03.020_bib28","first-page":"753","article-title":"Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates","volume":"121","author":"Guler","year":"1989","journal-title":"Acta Endocrinol."},{"key":"10.1016\/j.ymthe.2026.03.020_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000085760","article-title":"IGFs and IGFBPs in GH insensitivity","volume":"9","author":"Savage","year":"2005","journal-title":"Endocr. Dev."},{"key":"10.1016\/j.ymthe.2026.03.020_bib30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1203\/00006450-198609000-00002","article-title":"Biosynthetic somatomedin C (SM-C\/IGF-I) increases the length and weight of Snell dwarf mice","volume":"20","author":"van Buul-Offers","year":"1986","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymthe.2026.03.020_bib31","first-page":"3312","article-title":"Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome--a clinical research center study. GHIS Collaborative Group","volume":"81","author":"Backeljauw","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2026.03.020_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1677\/joe.0.0710037","article-title":"Stimulation of growth in the little mouse","volume":"71","author":"Beamer","year":"1976","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ymthe.2026.03.020_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1677\/joe.0.1360091","article-title":"Growth hormone deficiency in 'little' mice results in aberrant body composition, reduced insulin-like growth factor-I and insulin-like growth factor-binding protein-3 (IGFBP-3), but does not affect IGFBP-2, -1 or -4","volume":"136","author":"Donahue","year":"1993","journal-title":"J. Endocrinol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626002054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626002054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:24:30Z","timestamp":1793237070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626002054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1525001626002054"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.020","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A cartilage-targeted IGF-1-antibody fusion protein as a new therapeutic approach for IGF-1 deficiency","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}